HMGB1 晚峰与脓毒症结局:与慢性炎症性疾病协同作用的证据
本研究为既往随机临床试验的子研究,纳入 210 例全身炎症反应综合征合并革兰阴性感染患者,按 HMGB1 峰值早晚分组,检测系列血清 HMGB1、铁蛋白和干扰素-γ(IFNγ)。118 例(46.5%)至少合并一种炎症性疾病(糖尿病、慢性阻塞性肺疾病、慢性心力衰竭或慢性肾脏病)。HMGB1 晚峰组 28 天死亡率更高(OR 2.640;P=0.026)。晚峰与炎症性疾病共存对死亡率有协同影响(logistic 回归 OR 3.17;P=0.027)。晚峰在高铁蛋白血症患者中与更高的铁蛋白(P=0.035)和 IFNγ(P=0.002)水平相关。结论认为 HMGB1 晚峰与更差预后相关,尤其在合并慢性炎症性疾病的患者中。
要点
- 在全身炎症反应综合征合并革兰阴性感染患者中,HMGB1 晚峰与 28 天死亡率升高相关(OR 2.640;P=0.026)。
- HMGB1 晚峰与慢性炎症性疾病(糖尿病、慢性阻塞性肺疾病、慢性心力衰竭或慢性肾脏病)共存时协同增加死亡率(OR 3.17;P=0.027)。
- 210 例患者中 118 例(46.5%)至少合并一种炎症性疾病,提示此类基础病在脓毒症中常见。
- 在高铁蛋白血症患者中,HMGB1 晚峰与更高铁蛋白(P=0.035)和 IFNγ(P=0.002)水平相关。
- 作者结论认为 HMGB1 晚峰与更差预后相关,尤其合并慢性炎症性疾病者。
适用人群与场景
- 既往随机临床试验的子研究人群:全身炎症反应综合征合并革兰阴性感染患者。
- 至少合并一种炎症性疾病(糖尿病、慢性阻塞性肺疾病、慢性心力衰竭或慢性肾脏病)者占 118 例(46.5%)。
研究设计与关键结果
- 研究类型为既往随机临床试验的子研究,纳入 210 例全身炎症反应综合征合并革兰阴性感染患者,按 HMGB1 峰值早晚分组。
- 28 天死亡率在 HMGB1 晚峰组更高(OR 2.640;P=0.026)。
- HMGB1 晚峰与炎症性疾病共存对死亡率有协同影响(logistic 回归 OR 3.17;P=0.027)。
- 在高铁蛋白血症患者中,HMGB1 晚峰与更高铁蛋白(P=0.035)和 IFNγ(P=0.002)水平相关。
证据类型、等级与局限
- 证据类型:随机临床试验的子研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为 HMGB1 晚峰与更差预后相关,尤其合并慢性炎症性疾病的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
High mobility group box 1 (HMGB1) is released from macrophages as a late biomarker of sepsis. Conditions associated with pre-existing macrophage activation may modify HMGB1 expression. This study aimed to assess the impact of HMGB1 kinetics on 28-day mortality. In a sub-study of a previous randomized clinical trial among patients with systemic inflammatory response syndrome and gram-negative infections, patients were classified in early and late HMGB1 peak groups. Serial measurements of HMGB1, ferritin and interferon-gamma (IFNγ) were performed in all available sera. Two hundred ten patients were included; 118 (46.5%) had at least one inflammatory disease (diabetes, chronic obstructive pulmonary disease, chronic heart failure, or chronic renal disease). Mortality after 28 days was higher among patients with a late peak of HMGB1 (OR 2.640; P = 0.026). Co-existence of late peak and inflammatory disease synergistically impacted mortality (odds ratio of logistic regression analysis 3.17; P: 0.027). Late peak was concomitantly associated with higher values of ferritin (P = 0.035), and IFNγ (P = 0.002) among patients with hyperferritinemia. It is concluded that late HMGB1 peak was associated with worse prognosis, especially in patients with underlying chronic inflammatory conditions.
参考来源
- Karakike E, Adami ME, Lada M, et al. Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders. Shock. 2019. PMID: 30239421. doi:10.1097/SHK.0000000000001265
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。